News | Breast Imaging | November 28, 2021

Lunit announces FDA 510(k) clearance for Lunit INSIGHT MMG, now available for clinical use in U.S. hospitals and medical institutions

AI can detect breast cancer at an earlier stage; accuracy proven via studies published in major journals like JAMA Oncology and Lancet Digital Health

Lunit also holds FDA clearance for its chest X-ray triage AI solution, all to be introduced during RSNA 2021, booth #4545


Lunit, a leading medical AI provider, announced that the U.S. Food and Drug Administration (FDA) 510(k) has cleared its AI solution for breast cancer detection, Lunit INSIGHT MMG. Along with its chest X-ray triaging solution, Lunit INSIGHT CXR Triage, the company’s AI solution for both chest X-ray and mammography is now commercially available across the U.S.

“I am delighted to deliver the great news and to introduce Lunit INSIGHT MMG to healthcare professionals and institutions across the US,” said Brandon Suh, CEO of Lunit. “With our AI solution, we hope to increase the efficiency and accuracy of mammography screening as well as chest x-ray triaging. We can assist radiologists diagnose diseases at an earlier stage, helping patients be treated at the right time.”

Lunit INSIGHT MMG is one of the company’s most mature radiology products which analyzes mammography images with high accuracy. It provides the location of lesions suspicious of breast cancer and an abnormality score that reflects the AI’s confidence of the existence of detected lesions.

The product is trained with a large-scale data of more than 240,000 mammography cases that include up to 50,000 breast cancer cases and is known to show excellent performance in finding breast cancer at an earlier stage.

According to a study published in JAMA Oncology in 2020, Lunit INSIGHT MMG showed the best accuracy among three commercialized AI to identify breast cancer. It was found to have around 15% higher sensitivity compared to the other two algorithms. The FDA-cleared AI solution has been previously CE marked and approved for commercial sales in more than 35 countries worldwide.

“This is a huge milestone and business opportunity for us, as the U.S. is one of the largest and most important markets that covers more than 45% of the global breast imaging market,” added Suh. “Based on the FDA clearance, we will not only bring diagnostic value to medical professionals and patients in the U.S. but leverage our business to be a leading global provider of breast AI solution.”

Lunit INSIGHT MMG will be showcased at RSNA 2021, AI Showcase - booth #4545, Nov. 28 – Dec. 2, 2021, in Chicago.

For more information: https://www.lunit.io/en


Related Content

News | Digital Pathology

June 11, 2025 — Diagnostic laboratory leaders view digital pathology and artificial intelligence (AI) as pivotal to ...

Time June 12, 2025
arrow
News | Lung Imaging

June 11, 2025 — To prepare healthcare workforces and providers for an AI-driven future, Qure.ai has expanded its Global ...

Time June 11, 2025
arrow
News | Radiology Imaging

June 10, 2025 — CIVIE has announced the official launch of RadPod, an AI-driven, on-demand radiology platform designed ...

Time June 10, 2025
arrow
News | Ultrasound Imaging

June 4, 2025 — RadNet, Inc., a provider of high-quality, cost-effective diagnostic imaging services and digital health ...

Time June 09, 2025
arrow
News | Mammography

June 9, 2025 — A new independent, peer-reviewed study published in the journal Clinical Breast Cancer reinforces the ...

Time June 09, 2025
arrow
News | Imaging Software Development

June 05, 2025 — Nano-X Imaging Ltd. has announced that its deep-learning medical imaging analytics subsidiary, Nanox AI ...

Time June 05, 2025
arrow
News | Prostate Cancer

June 5, 2025 – Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer ...

Time June 05, 2025
arrow
News | Ultrasound Imaging

June 3, 2025 — In a collaborative study between the Departments of Radiology at the Children’s Hospital of Philadelphia ...

Time June 04, 2025
arrow
News | Breast Imaging

June 2, 2025 — Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S ...

Time June 02, 2025
arrow
News | PET Imaging

May 30, 2025 — GE HealthCare recently announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) ...

Time May 30, 2025
arrow
Subscribe Now